Publications by authors named "M Lisker-Melman"
Background And Aims: Semaglutide has been studied in patients with metabolic dysfunction-associated steatohepatitis (MASH) due to potential benefit from weight loss on liver inflammation. However, preclinical studies suggest that MASH improvement may be independent of weight loss. We aim to assess the impact of semaglutide on MASH in relation to weight loss.
View Article and Find Full Text PDF: Metabolic-dysfunction-associated steatotic liver disease or MASLD is the main cause of chronic liver diseases in children, and it is estimated to affect 35% of children living with obesity. This study aimed to identify metabolic phenotypes associated with two advanced stages of MASLD (hepatic steatosis and hepatic steatosis plus fibrosis) in Mexican children with obesity. : This is a cross-sectional analysis derived from a randomized clinical trial conducted in children and adolescents with obesity aged 8 to 16 years.
View Article and Find Full Text PDFArticle Synopsis
- Hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) are emerging markers for assessing HBV activity, especially for those with HIV co-infection.
- A study compared HBV marker levels between patients with chronic HBV who were co-infected with HIV and those with HBV only, revealing that HBV markers were generally higher in the HBV-HIV group among HBeAg+ individuals.
- The findings suggest that HBV marker levels are influenced by HIV co-infection status and that they vary based on HBeAg status, with HBV RNA being a more reliable marker of transcriptional activity than HBcrAg.
Article Synopsis
- Researchers studied the effectiveness of HBV RNA and HBcrAg, two virological markers, in predicting various disease activity events in patients with chronic hepatitis B (CHB).
- They analyzed data from participants in a North American study to see if these markers could enhance existing prediction models already based on demographic, clinical, and viral factors.
- The findings indicated that while HBV RNA and HBcrAg are predictive of certain clinical events, they do not significantly improve the accuracy of models using more commonly available markers.